The prospective record-breaking obesity drug tirzepatide raises concerns about affordability
Author:
Affiliation:
1. Department of Pharmacology and Therapeutics , Seth G.S. Medical College and KEM Hospital , Mumbai , India
2. State Program Officer, Women and Child Development Commissionerate , Government of Maharashtra , Pune , India
Publisher
Walter de Gruyter GmbH
Subject
Drug Discovery,Pharmacology,General Medicine,Physiology
Link
https://www.degruyter.com/document/doi/10.1515/jbcpp-2023-0129/pdf
Reference7 articles.
1. Jastreboff, AM, Aronne, LJ, Ahmad, NN, Wharton, S, Connery, L, Alves, B, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387:205–16. https://doi.org/10.1056/nejmoa2206038.
2. Liu, J, Ting, JP, Al‐Azzam, S, Ding, Y, Afshar, S. Therapeutic advances in diabetes, autoimmune, and neurological diseases. Int J Mol Sci 2021;22:1–71. https://doi.org/10.3390/ijms22062805.
3. Levi, J, Wang, J, Venter, F, Hill, A. Estimated minimum prices and lowest available national prices for antiobesity medications: improving affordability and access to treatment. Obesity 2023;31:1270–9. https://doi.org/10.1002/oby.23725.
4. Mylona, EK, Benitez, G, Shehadeh, F, Fleury, E, Mylonakis, SC, Kalligeros, M, et al.. The association of obesity with health insurance coverage and demographic characteristics: a statewide cross-sectional study. Medicine 2020;99:e21016. https://doi.org/10.1097/md.0000000000021016.
5. Finkelstein, EA, Kruger, E, Karnawat, S. Cost-Effectiveness Analysis of Qsymia for Weight Loss. Pharmacoeconomics 2015;33:699–706. https://doi.org/10.1007/s40273-014-0182-6.
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Can small molecule GLP-1 agonists be the next first-line drugs in type-2 diabetes mellitus?;Journal of Basic and Clinical Physiology and Pharmacology;2023-12-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3